Literature DB >> 16925498

Lipid-lowering effects of statins: a comparative review.

Michael H Davidson1, Jennifer G Robinson.   

Abstract

The pharmacological regulation of lipid metabolism in patients with dyslipidaemia is unequivocally associated with significant reductions in risk for cardiovascular morbidity and mortality. There is strong clinical trial data to support of the use of statin therapies in the settings of both primary and secondary prevention. This paper addresses: i) the mechanisms of action of antilipidaemic medications; ii) dosing regimens and the pharmacokinetic differences among drugs of the same class; iii) risk for drug interactions; and iv) reviews the clinical trial evidence used to support the use of particular antilipidaemic medications in specific physiological settings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16925498     DOI: 10.1517/14656566.7.13.1701

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  13 in total

1.  Statin adjunctive therapy shortens the duration of TB treatment in mice.

Authors:  Noton K Dutta; Natalie Bruiners; Michael L Pinn; Matthew D Zimmerman; Brendan Prideaux; Véronique Dartois; Maria L Gennaro; Petros C Karakousis
Journal:  J Antimicrob Chemother       Date:  2016-02-21       Impact factor: 5.790

Review 2.  Fenofibrate and metabolic syndrome.

Authors:  Aldi T Kraja; Michael A Province; Robert J Straka; Jose M Ordovas; Ingrid B Borecki; Donna K Arnett
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2010-06       Impact factor: 2.895

3.  Squalene synthase inhibition: a novel target for the management of dyslipidemia.

Authors:  Michael H Davidson
Journal:  Curr Atheroscler Rep       Date:  2007-01       Impact factor: 5.113

Review 4.  Is a statin as part of a polypill the answer?

Authors:  Jennifer G Robinson
Journal:  Curr Atheroscler Rep       Date:  2009-01       Impact factor: 5.113

Review 5.  Adjunctive interventions in myocardial infarction: the role of statin therapy.

Authors:  Peter H Jones; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2008-04       Impact factor: 5.113

6.  Bioprospecting lovastatin production from a novel producer Cunninghamella blakesleeana.

Authors:  Janani Balraj; Karunyadevi Jairaman; Vidhya Kalieswaran; Angayarkanni Jayaraman
Journal:  3 Biotech       Date:  2018-08-03       Impact factor: 2.406

7.  Genetic determinants of statin intolerance.

Authors:  Jisun Oh; Matthew R Ban; Brooke A Miskie; Rebecca L Pollex; Robert A Hegele
Journal:  Lipids Health Dis       Date:  2007-03-21       Impact factor: 3.876

8.  Hydrazone and Oxime Olefination via Ruthenium Alkylidenes.

Authors:  Daniel J Nasrallah; Troy E Zehnder; Jacob R Ludwig; Daniel C Steigerwald; John J Kiernicki; Nathaniel K Szymczak; Corinna S Schindler
Journal:  Angew Chem Int Ed Engl       Date:  2022-03-29       Impact factor: 16.823

9.  Changes in cholesterol kinetics following sugar cane policosanol supplementation: a randomized control trial.

Authors:  Amira N Kassis; Peter J H Jones
Journal:  Lipids Health Dis       Date:  2008-04-30       Impact factor: 3.876

10.  CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort.

Authors:  Joseph P Kitzmiller; Jasmine A Luzum; Damiano Baldassarre; Ronald M Krauss; Marisa W Medina
Journal:  Pharmacogenet Genomics       Date:  2014-10       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.